Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
Platelet-reducing medication recalled | Contrast media shortage hits CT imaging | Empagliflozin & vascular aging
Wednesday, May 25, 2022
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

FDA announces recall of platelet-reducing medication due to risk of clotting or other adverse cardiovascular outcomes

The medication failed a routine dissolution test, meaning it could lose its effectiveness. 

READ MORE >
Anagrelide capsules FDA recall Teva Pharmaceuticals USA
Share on Twitter Share on Facebook Share on Linkedin

FDA announces recall of platelet-reducing medication due to risk of clotting or other adverse cardiovascular outcomes

Share on Twitter Share on Facebook Share on Linkedin
Anagrelide capsules FDA recall Teva Pharmaceuticals USA
The medication failed a routine dissolution test, meaning it could lose its effectiveness. 
READ MORE >

VIDEO: Contrast media shortage impacting cardiac CT imaging

Eric Williamson, MD, president of the Society of Cardiovascular Computed Tomography (SCCT) and professor of radiology at Mayo Clinic, explains how the iodine contrast shortage is causing issues for cardiac CT imaging and ways this can be mitigated.

READ MORE >
Eric Williamson, MD, MSCCT, the president of the Society of Cardiovascular Computed Tomography (SCCT) and professor of radiology at Mayo Clinic, explains how the iodine contrast shortage is causing issues for cardiac CT imaging. He discusses ways imagers can stretch they iodine contrast supplies and some technologies that might help conserve contrast. #contrastshortage
Share on Twitter Share on Facebook Share on Linkedin

VIDEO: Contrast media shortage impacting cardiac CT imaging

Share on Twitter Share on Facebook Share on Linkedin
Eric Williamson, MD, MSCCT, the president of the Society of Cardiovascular Computed Tomography (SCCT) and professor of radiology at Mayo Clinic, explains how the iodine contrast shortage is causing issues for cardiac CT imaging. He discusses ways imagers can stretch they iodine contrast supplies and some technologies that might help conserve contrast. #contrastshortage
Eric Williamson, MD, president of the Society of Cardiovascular Computed Tomography (SCCT) and professor of radiology at Mayo Clinic, explains how the iodine contrast shortage is causing issues for cardiac CT imaging and ways this can be mitigated.
READ MORE >

Empagliflozin may reverse vascular aging, lower CVD risk

The SGLT2 inhibitor is already known as an effective medication for both type 2 diabetes and heart failure.

READ MORE >
heart_body_blood_bloodvessel.jpg
Share on Twitter Share on Facebook Share on Linkedin

Empagliflozin may reverse vascular aging, lower CVD risk

Share on Twitter Share on Facebook Share on Linkedin
heart_body_blood_bloodvessel.jpg
The SGLT2 inhibitor is already known as an effective medication for both type 2 diabetes and heart failure.
READ MORE >

3D cardiac modeling solution for VT ablation receives FDA clearance

The new software solution was designed with ventricular tachycardia ablation and other cardiac ablation procedures in mind.

READ MORE >
inHEART Medical, an international healthcare company with offices in France and the United States, has received clearance from the U.S. Food and Drug Administration (FDA) for its new 3D visualization software designed to improve the management of ventricular tachycardia (VT) ablation and other cardiac ablation procedures.
Share on Twitter Share on Facebook Share on Linkedin

3D cardiac modeling solution for VT ablation receives FDA clearance

Share on Twitter Share on Facebook Share on Linkedin
inHEART Medical, an international healthcare company with offices in France and the United States, has received clearance from the U.S. Food and Drug Administration (FDA) for its new 3D visualization software designed to improve the management of ventricular tachycardia (VT) ablation and other cardiac ablation procedures.
The new software solution was designed with ventricular tachycardia ablation and other cardiac ablation procedures in mind.
READ MORE >

Featured Articles

Left bundle branch block after TAVR hurts outcomes, even when no permanent pacemaker is required

Researchers tracked data from more than 2,000 TAVR patients, focusing on cardiovascular mortality and hospitalizations for heart failure. 

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Left bundle branch block after TAVR hurts outcomes, even when no permanent pacemaker is required

Share on Twitter Share on Facebook Share on Linkedin
Researchers tracked data from more than 2,000 TAVR patients, focusing on cardiovascular mortality and hospitalizations for heart failure. 
READ MORE >

FDA approves tirzepatide, Eli Lilly’s new type 2 diabetes drug, and the company shares an estimated price

The medication, sold under the name Mounjaro, will be available in six different doses and come in an auto-injector pen.

READ MORE >
The FDA has cleared tirzepatide (Mounjaro) from Eli Lilly, a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide receptor agonist (GLP-1) for improving glycemic control among adults with type 2 diabetes.
Share on Twitter Share on Facebook Share on Linkedin

FDA approves tirzepatide, Eli Lilly’s new type 2 diabetes drug, and the company shares an estimated price

Share on Twitter Share on Facebook Share on Linkedin
The FDA has cleared tirzepatide (Mounjaro) from Eli Lilly, a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide receptor agonist (GLP-1) for improving glycemic control among adults with type 2 diabetes.
The medication, sold under the name Mounjaro, will be available in six different doses and come in an auto-injector pen.
READ MORE >

In Other News

FDA posts guidance on managing risk of drug shortages

The Food & Drug Administration has drafted guidelines to help U.S. healthcare better prepare for and respond to events associated with these situations.

READ MORE >
drugs.jpg
Share on Twitter Share on Facebook Share on Linkedin

FDA posts guidance on managing risk of drug shortages

Share on Twitter Share on Facebook Share on Linkedin
drugs.jpg
The Food & Drug Administration has drafted guidelines to help U.S. healthcare better prepare for and respond to events associated with these situations.
READ MORE >

Surgeon General warns of healthcare workforce burnout

A new advisory from the U.S. Surgeon General included several recommendations for addressing burnout.

READ MORE >
nurse.jpg
Share on Twitter Share on Facebook Share on Linkedin

Surgeon General warns of healthcare workforce burnout

Share on Twitter Share on Facebook Share on Linkedin
nurse.jpg
A new advisory from the U.S. Surgeon General included several recommendations for addressing burnout.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Medtech giant makes big move | The world’s top hospitals for heart surgery | New CPT codes | PET vs. SPECT | TAVR tech recalled
AI is gaining ground, but clinicians run the show | Siemens Healthineers doubles down | Electrophysiologist compensation
News Alert: FDA shares warning about heart valve tech after patient death
Cardiologist pay & productivity are up | FDA clears PE thrombectomy devices | Cardiology tech in spotlight | Gore's new approval
Cardiology salaries on the rise | The climbing costs of care | M&A trends | Siemens Healthineers, J&J make big business moves
Major MRI trends | Blood thinner recalled | When to perform PCI before TAVR | How to build a CCTA program | Steroids & the heart
CMS boosts coverage for heart failure tech | FDA approves CardioMEMS updates | LVADs linked to strokes, other risks
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme